Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib and Durvalumab in Premenopausal Metastatic Breast Cancer
NCT05720260Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib, durvalumab in breast cancer, sponsored by National Taiwan University Hospital. Started Jan 2023; status: recruiting.
02
Drugs
capivasertibdurvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05720260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720260.